Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
Haemonetics (NYSE: HAE) has completed the sale of its whole blood assets to GVS, S.p.A for a total consideration of up to $67.8 million. The deal includes $45.3 million upfront payment and potential earn-outs of up to $22.5 million over four years.
The transaction encompasses Haemonetics' whole blood collection, processing and filtration solutions portfolio, along with its Covina, California manufacturing facility and related assets in Tijuana, Mexico. The company plans to use the proceeds for general corporate purposes and growth initiatives.
Haemonetics will maintain its Blood Center business, continuing to manufacture and provide apheresis solutions for automated blood collection, including devices and disposable kits for platelets, plasma, and red cells collection.
Haemonetics (NYSE: HAE) ha completato la vendita delle sue attività relative al sangue intero a GVS, S.p.A per un corrispettivo totale di fino a 67,8 milioni di dollari. L'accordo include un pagamento anticipato di 45,3 milioni di dollari e potenziali guadagni di fino a 22,5 milioni di dollari in quattro anni.
La transazione comprende il portafoglio di soluzioni per la raccolta, lavorazione e filtraggi del sangue intero di Haemonetics, insieme al suo stabilimento di produzione a Covina, California, e agli asset correlati a Tijuana, Messico. L'azienda prevede di utilizzare i proventi per fini aziendali generali e iniziative di crescita.
Haemonetics manterrà la sua attività di Blood Center, continuando a produrre e fornire soluzioni di aferesi per la raccolta automatizzata di sangue, inclusi dispositivi e kit monouso per la raccolta di piastrine, plasma e globuli rossi.
Haemonetics (NYSE: HAE) ha completado la venta de sus activos de sangre entera a GVS, S.p.A por un valor total de hasta 67,8 millones de dólares. El acuerdo incluye un pago inicial de 45,3 millones de dólares y posibles ganancias de hasta 22,5 millones de dólares durante cuatro años.
La transacción abarca el portafolio de soluciones para la recolección, procesamiento y filtración de sangre entera de Haemonetics, junto con su planta de fabricación en Covina, California, y los activos relacionados en Tijuana, México. La empresa planea utilizar los ingresos para fines corporativos generales e iniciativas de crecimiento.
Haemonetics mantendrá su negocio de Blood Center, continuando con la fabricación y provisión de soluciones de aferesis para la recolección automatizada de sangre, incluidos dispositivos y kits desechables para la recolección de plaquetas, plasma y glóbulos rojos.
Haemonetics (NYSE: HAE)는 GVS, S.p.A에 전체 혈액 자산 판매를 완료했으며, 총 금액은 최대 6780만 달러에 달합니다. 이 거래에는 4530만 달러의 선불 지급과 향후 4년 동안 최대 2250만 달러의 성과급이 포함됩니다.
이번 거래는 Haemonetics의 전체 혈액 수집, 처리 및 필터링 솔루션 포트폴리오를 포함하며, 캘리포니아 주 코비나의 제조 시설과 멕시코 티후아나의 관련 자산도 포함됩니다. 이 회사는 수익을 일반 기업 목적과 성장 이니셔티브에 사용할 계획입니다.
Haemonetics는 Blood Center 비즈니스를 유지하여 자동 혈액 수집을 위한 아페레시스 솔루션을 계속 제조 및 제공하며, 여기에는 혈소판, 플라즈마 및 적혈구 수집을 위한 장치 및 일회용 키트가 포함됩니다.
Haemonetics (NYSE: HAE) a terminé la vente de ses actifs de sang total à GVS, S.p.A pour un montant total de jusqu'à 67,8 millions de dollars. L'accord comprend un paiement initial de 45,3 millions de dollars et des éventuelles primes allant jusqu'à 22,5 millions de dollars sur quatre ans.
La transaction couvre le portefeuille de solutions de collecte, de traitement et de filtration de sang total de Haemonetics, ainsi que son usine de fabrication à Covina, en Californie, et les actifs connexes à Tijuana, au Mexique. L'entreprise prévoit d'utiliser les recettes à des fins d'entreprise générales et d'initiatives de croissance.
Haemonetics conservera son activité de Blood Center, continuant à fabriquer et à fournir des solutions d'aferèse pour la collecte automatisée de sang, y compris des dispositifs et des kits jetables pour la collecte de plaquettes, de plasma et de globules rouges.
Haemonetics (NYSE: HAE) hat den Verkauf seiner Ganzblutvermögen an GVS, S.p.A für eine Gesamtsumme von bis zu 67,8 Millionen US-Dollar abgeschlossen. Der Deal umfasst eine Vorauszahlung von 45,3 Millionen US-Dollar und mögliche Zusatzvergütungen von bis zu 22,5 Millionen US-Dollar über vier Jahre.
Die Transaktion umfasst das Portfolio von Haemonetics für die Sammlung, Verarbeitung und Filtration von Ganzblut, einschließlich seiner Produktionsstätte in Covina, Kalifornien, sowie verwandte Vermögenswerte in Tijuana, Mexiko. Das Unternehmen plant, die Einnahmen für allgemeine Unternehmenszwecke und Wachstumsinitiativen zu verwenden.
Haemonetics wird sein Geschäft mit Blood Center beibehalten und weiterhin Aphareselösungen für die automatisierte Blutentnahme herstellen und bereitstellen, einschließlich Geräte und Einweg-Sets für die Sammlung von Thrombozyten, Plasma und roten Blutkörperchen.
- Sale generates immediate cash influx of $45.3M with potential additional $22.5M in earn-outs
- Proceeds to be invested in growth initiatives
- Company retains core apheresis solutions business
- Divestment of whole blood collection business segment reduces revenue streams
Insights
The sale of Haemonetics' whole blood assets represents a strategic move to streamline operations and focus on higher-margin business segments. The
This divestiture aligns with industry trends of focusing on core competencies and higher-growth segments. By retaining the apheresis solutions business while divesting whole blood operations, HAE positions itself to concentrate resources on more profitable automated collection technologies. The deal includes strategic asset transfers, notably the Covina facility and Tijuana equipment, which should optimize the operational footprint and potentially improve margins.
The timing of this announcement before Q3 earnings suggests management's confidence in the transaction's positive impact on fiscal 2025 performance. For investors, this represents a calculated move to enhance shareholder value through business optimization and potential reinvestment in growth initiatives.
This divestiture strengthens HAE's market positioning in the specialized blood technology sector. The blood collection market is bifurcating between commodity-like whole blood collection and higher-value automated processes. By selling the whole blood segment to GVS, a recognized filtration specialist, HAE can now focus entirely on the more technologically advanced apheresis market, where barriers to entry are higher and profit margins typically stronger.
The deal's structure reveals careful consideration of market dynamics. GVS gains immediate access to established whole blood collection products and manufacturing capabilities, while HAE maintains exposure to potential upside through earn-outs. The choice of GVS as the buyer is strategic - their expertise in filtration solutions could potentially enhance the product line's competitiveness, benefiting both parties through the earn-out period.
For HAE's competitive position, this transaction represents a shift from being a broad-spectrum blood technology provider to a focused player in premium segments. This specialization strategy could lead to improved market perception and potentially higher valuation multiples, as investors typically reward companies with clearer, more focused business models.
The transaction comprises a total cash consideration of up to
Haemonetics' Blood Center business will continue to manufacture and provide customers with its full line of apheresis solutions for automated blood collection. These include devices and disposable kits that support a variety of apheresis collections, including platelets, plasma and red cells, and ensure efficient blood center operations.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) the anticipated benefits to Haemonetics arising from the completion of the transaction; (ii) statements regarding Haemonetics' strategies, positioning, resources, capabilities and expectations for future performance; and (iii) the assumptions underlying or relating to any such statement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.
Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the failure to realize the anticipated benefits of the transaction, including from non-achievement of any commercial milestone required to receive all or part of the additional contingent consideration, or the transaction having an unanticipated impact; Haemonetics' ability to predict accurately the demand for its products and products under development and to develop strategies to address its markets successfully; and the impact of competitive products and pricing and technical innovations that could render products marketed or under development by Haemonetics obsolete. These and other factors are identified and described in more detail in Haemonetics' filings with the
Investor Contacts: | ||
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations | |
(781) 356-9763 | (203) 733-4987 | |
Media Contact: | ||
Josh Gitelson, Sr. Director-Global Communications | ||
(781) 356-9776 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-completes-sale-of-whole-blood-assets-to-gvs-spa-302350348.html
SOURCE Haemonetics Corporation
FAQ
What is the total value of Haemonetics (HAE) whole blood assets sale to GVS?
What assets did Haemonetics (HAE) sell to GVS in the January 2025 deal?
How will Haemonetics (HAE) use the proceeds from the GVS asset sale?
What blood-related products will Haemonetics (HAE) continue to manufacture after the GVS sale?
When will Haemonetics (HAE) provide details about the financial impact of the GVS sale?
